Get started
Author

Danila Hauswald

Institution: Tubulis (Germany)
Observed institution: Tubulis (Germany)
ORCID: 0009-0002-5573-4397
Observed ORCID: 0009-0002-5573-4397
OpenAlex ID: A5094219283
TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al. · Molecular Cancer Therapeutics · 7
PDF
Abstract 2622: TUB-040, a novel Napi2b-targeting ADC built with ethynylphosphonamidate conjugation chemistry, demonstrates high and long-lasting anti-tumor efficacy via Topoisomerase-I inhibition and excellent tolerability predictive of a wide therapeutic window in humans
2024 · Saskia Schmitt, Isabelle Mai, et al. · Cancer Research · 7
Abstract 2623: Enabling 5T4 for targeted cancer therapy: TUB-030, a novel ADC built with ethynylphosphonamidate conjugation chemistry, shows long-lasting anti-tumor activity via Topoisomerase-I inhibition with an optimized therapeutic index
2024 · Saskia Schmitt, Isabelle Mai, et al. · Cancer Research · 3
Supplementary Table 1 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Table 2 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 10 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 5 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 4 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 6 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 3 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 7 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Methods 1 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 8 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 2 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 9 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Supplementary Figure 1 from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Data from TUB-040, a Homogeneous and Hydrophilic NaPi2b-Targeting ADC with Stably Linked Exatecan, Exhibits Long-lasting Antitumor Activity and a Well-Tolerated Safety Profile
2025 · Annette M. Vogl, Saskia Schmitt, et al.
Works count: 17
Citation count: 17
H-index: 3
I10-index:
Year
Topic
Type